Biotech

All Articles

Sanofi fails MS study, dealing one more impact to Denali pact

.Sanofi has actually quit a phase 2 ordeal of Denali Therapeutics-partnered oditrasertib in numerous...

Turnstone gives up 60%, shakes up C-suite to stretch out cash

.Turnstone Biologics is lowering its own head count through 60% as well as agitating its C-suite so ...

Gilead loses hope on $15M MASH bet after weighing preclinical records

.In a year that has actually found an authorization as well as a range of readouts for metabolic dys...

Texas biotech centers cancer cells pact, pins hopes on weight problems

.Alaunos Therapies is actually axing an arrangement along with Precigen, surrendering licensing civi...

Capricor allotments extra information for DMD therapy after launching BLA

.Capricor Rehabs is taking a triumph lap for their stage 2 Duchenne muscle dystrophy (DMD) trial. At...

FDA areas Kezar lupus trial in grip complying with 4 client fatalities

.The FDA has actually placed Kezar Life Sciences' lupus trial on grip after the biotech flagged 4 de...

Phase 3 Academic Rock test reaches SMA target, delivering stock up 200%

.A stage 3 trial of Academic Stone's vertebral muscle degeneration (SMA) prospect has actually struc...

CAMP 4 is newest to eye IPO, while Upstream point out $182M plan

.RNA biotech CAMP4 Therapeutics has actually marked out plans for a $67 thousand IPO, along with inf...

Galecto gets leukemia drug, drops bone cancer cells possession in pivot

.A year after the breakdown of an idiopathic lung fibrosis prospect sent out Galecto on a seek redem...

Judo tosses down $100M to knock senseless renal ailment

.Taking the floor covering is Judo Bio, an up-and-coming biotech equipped with $100 million to creat...